{"organizations": [], "uuid": "6e64e355d35e0487213bb6e879bdbb4041da3e1d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-mersana-therapeutics-q4-loss-per-s/brief-mersana-therapeutics-q4-loss-per-share-0-61-idUSASC09TXY", "country": "US", "domain_rank": 408, "title": "BRIEF-Mersana Therapeutics Q4 Loss Per Share $0.61", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-28T14:43:00.000+03:00", "replies_count": 0, "uuid": "6e64e355d35e0487213bb6e879bdbb4041da3e1d"}, "author": "", "url": "https://www.reuters.com/article/brief-mersana-therapeutics-q4-loss-per-s/brief-mersana-therapeutics-q4-loss-per-share-0-61-idUSASC09TXY", "ord_in_thread": 0, "title": "BRIEF-Mersana Therapeutics Q4 Loss Per Share $0.61", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "mersana therapeutics inc", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 45 AM / Updated 9 minutes ago BRIEF-Mersana Therapeutics Q4 Loss Per Share $0.61 Reuters Staff \nMarch 28 (Reuters) - Mersana Therapeutics Inc: \n* MERSANA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES * Q4 LOSS PER SHARE $0.61 \n* Q4 EARNINGS PER SHARE VIEW $-0.50 â€” THOMSON REUTERS I/B/E/S \n* ENROLLMENT ON TRACK FOR PHASE 1 TRIAL OF XMT-1522 PATIENTS WITH ADVANCED TUMORS EXPRESSING HER2 \n* COLLABORATION REVENUE FOR Q4 2017 WAS ABOUT $3.3 MILLION VERSUS $12.0 MILLION FOR SAME PERIOD IN 2016 \n* CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DECEMBER 31, 2017 WERE $125.2 MILLION \n* MERSANA THERAPEUTICS - EXPECTS CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL ENABLE CO TO FUND OPERATING PLAN THROUGH AT LEAST MID-2019 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-28T14:43:00.000+03:00", "crawled": "2018-03-28T15:06:25.004+03:00", "highlightTitle": ""}